Literature DB >> 30234712

The Promising Effects of Transplanted Umbilical Cord Mesenchymal Stem Cells on the Treatment in Traumatic Brain Injury.

Lifeng Qi1,2, Xinhong Xue2, Jijun Sun2, Qingjian Wu3, Hongru Wang2, Yan Guo2, Baoliang Sun4.   

Abstract

Many studies have reported the recovery ability of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for neural diseases. In this study, the authors explored the roles of UC-MSCs to treat the traumatic brain injury. Umbilical cord-derived mesenchymal stem cells were isolated from healthy neonatal rat umbilical cord immediately after delivery. The traumatic brain injury (TBI) model was formed by the classical gravity method. The authors detected the behavior changes and measured the levels of inflammatory factors, such as interleukin-lβ and tumor necrosis factor-α by enzyme linked immunosorbent assay (ELISA) at 1, 2, 3, 4 weeks after transplantation between TBI treated and untreated with UC-MSCs. Simultaneously, the expression of glial cell line-derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) were measured by real-time-polymerase chain reaction and ELISA.The authors found that the group of transplantation UC-MSCs has a significant improvement than other group treated by phosphate buffered saline. In the behavioral test, the Neurological Severity Scores of UC-MSCs + TBI group were lower than TBI group (P < 0.05), but not obviously higher than control group at 2, 3, and 4week, respectively. The inflammatory factors are significantly reduced comparison with TBI group (P < 0.05), but both GDNF and BDNF were higher than TBI group (P < 0.05). The results indicated that UC-MSCs might play an important role in TBI recovery through inhibiting the release of inflammatory factors and increasing the expression of GDNF and BDNF.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30234712      PMCID: PMC6200375          DOI: 10.1097/SCS.0000000000005042

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


Traumatic brain injury (TBI) is a high-incidence injury, which can cause severe brain damage or even disability. The patients suffered from TBI showed somewhat damaged neurological symptoms, such as intracranial hypertension, or lost the cognitive competence totally.[1-3] But the process of the treatment is still unsatisfied. Thus, the TBI treatment is mainly focused on the survival of nerve in the injury domain. Recently, umbilical cord-derived mesenchymal stem cells (UC-MSC) is a new focus of research in medicine and pharmacy. Numerous studies have reported that UC-MSCs, as a kind of pluripotent stem cells, can differentiate into microglial cells and oligodendrocytes, and which lead the new direction for cell therapy.[4,5] Umbilical cord-derived mesenchymal stem cells might be used to treat a lot of neurodegenerative disease, such as Alzheimer disease, Parkinson disease, and stroke. Previous studies found that stem cells can replace the apoptotic cells and release some neurotrophic factors to restore the damage tissue.[6-8] Further studies also showed that Stem cells and suppress inflammation by inhibiting the secretion of some proinflammatory cytokines.[9,10] Traumatic brain injury is a complex pathological process, involving brain damage causing inflammation.[11,12] Therefore, we expected to find more possible mechanism of UC-MSCs in TBI models to facilitate the treatment of TBI.

METHODS

Animal Model and Behavioral Measures

Thirty 6–8-week-old male SD rats, weighing 185 to 200 g and 20 pregnant rats were incorporated into our experiment. All animal experiments met the requirement of Animal ethics Committee. The method we used to make TBI model was conducted on the basis of previous studies.[13,14] We divided the male rats into 3 groups (TBI group treat with phosphate buffered saline (PBS), TBI+UC-MSCs group, control group). All rats were anesthetized by intraperitoneal injection of 4% chloral hydrate. We performed this experiment and the behavioral measure according to the described as prevent research.[15] Animals were assessed by Neurological Severity Scores (NSS).[16]

Isolation, Culturing, and Flow Cytometry Analysis of Umbilical Cord-Derived Mesenchymal Stem Cells

The total UC-MSCs fraction was obtained by digesting with 0.25% trypsin as described previously.[17,18] The number of 1 × 106 cells were cultured with fresh medium contained DMEM/F12, N2, P/S, FGF2 for 7 days in cell incubator under 37°C and 5% CO2. Subsequently, we subcultured the cells when they reach 80% content, and as the same way, we subcultured the cells to the third generation.[19-21] We analyzed the characteristics of cultured UC-MSCs with flow cytometry (BD Biosience, San Jose, CA). The UC-MSC surface marker included CD16, CD29, CD34, CD45, CD73, CD90 (BD Biosience).

Cell Transplantation

The UC-MSCs were diluted with PBS to a cell concentration of 5 × 105 cells/μL. And 6 μL of the cell suspension or PBS was immediately transplanted into the damage place of TBI+UC-MSCs group after TBI model structured. PBS was injected into TBI group and control group.

Immunohistochemistry

The rats were sacrificed after UC-MSCs were transplanted 1, 2, 3, 4 weeks and at the same time they were perfused with 4% paraformaldehyde. We obtained and fixed the whole rat brains in 4% paraformaldehyde for 24 hours. Subsequently, we performed the protocol of immunohistochemistry as described previously to stain the Glial cells’ marker (GFAP, Dako rabbit 1:500). We used the fluorescence microscope (Nikon, Ti) to take all images of the brain slices what were stained.[22,23]

Real-Time Quantitative Polymerase Chain Reaction and Enzyme Linked Immunosorbent Assay

We isolated total RNA with Trizol (Sigma-Aldrich, St Louis, MO), and reversed transcripted with PrimeScript real-time reagent Kit with genomic DNA Eraser (Takara Bio, Kusatsu, Japan). The reactive buffer for real-time quantitative polymerase chain reaction (PCR) was Power SYBR Green PCR Master Mix (Thermo Fisher Scientific, Waltham, MA). The primer sequence was described as follows. GDNF-F: TTATTCAAGCCACCATCA GDNF-R: AGGAACCGCTACAATATC BDNF-F: CTGATAGTTCTGTCCATTC BDNF-R: TCCACTCCTAAGATGAAG GAPDH-F: GCCTTCCGTGTTCCTACC GAPDH-R: CCTGCTTCACCACCTTCTT We vibrated the damaged or cell transplanted tissue obtained from 3 groups with radio immunoprecipitation assay lysis buffer, and the antibodies to GDNF and BDNF were used to detect the expression of GDNF or BDNF.

Data Analysis

The data were analyzed with the Students t test (SPSS statistics software 20.1, Chicago, IL).

RESULTS

Isolation and Cultured of Umbilical Cord-Derived Mesenchymal Stem Cells

The total UC-MSCs fraction was obtained by digesting with 0.25% trypsin. After isolation of UC-MSCs, we immediately cultured them with fresh medium. And then a part of cells were detected in the characterization with flow cytometry. As a result, the average expression of CD16, CD29, CD34, CD45, CD73, and CD90 accounts for 32.10% ± 2.97%, 72.10% ± 0.63%, 3.52% ± 0.86%, 92.25% ± 8.95%, 19.30% ± 4.13%, and 42.36% ± 0.32% of the UC-MSCs respectively as shown in Figure 1.
FIGURE 1

Flow cytometry analysis of the UC-MSCs. (A) Expression of surface markers of UC-MSCs. (B) The average rate of CD16, CD29, CD34, CD45, CD73, CD90. UC-MSCs, umbilical cord-derived mesenchymal stem cells.

Flow cytometry analysis of the UC-MSCs. (A) Expression of surface markers of UC-MSCs. (B) The average rate of CD16, CD29, CD34, CD45, CD73, CD90. UC-MSCs, umbilical cord-derived mesenchymal stem cells.

Behavioral Measures of Traumatic Brain Injury Rats Transplanted Umbilical Cord-Derived Mesenchymal Stem Cells

To investigate whether UC-MSCs have an impact on respiration to the damage neuron. we tested the behavior after cells were transplanted 1, 2, 3, 4 weeks, respectively, by evaluating NSS in each group (Fig. 2). We found that the score of TBI + UC-MSCs group was significantly lower than TBI group (P < 0.05).
FIGURE 2

The score of Neurological Severity Scores (NSS) of the groups. The scores of TBI+UC-MSCs group were lower than TBI group after UC-MSCs were transplanted 2, 3, 4 weeks (∗P < 0.05), 2-way ANOVA with post hoc test. TBI, traumatic brain injury; UC-MSCs, umbilical cord-derived mesenchymal stem cells.

The score of Neurological Severity Scores (NSS) of the groups. The scores of TBI+UC-MSCs group were lower than TBI group after UC-MSCs were transplanted 2, 3, 4 weeks (∗P < 0.05), 2-way ANOVA with post hoc test. TBI, traumatic brain injury; UC-MSCs, umbilical cord-derived mesenchymal stem cells.

The Differentiation of Umbilical Cord-Derived Mesenchymal Stem Cells In Vivo

To investigate the survival and the differentiation of UC-MSCs in vivo, we performed immunohistochemistry after UC-MSCs were transplanted 1, 2, 3, 4 weeks. Nerve-specific antibody of rat was used to label UC-MSCs. The images of immunohistochemistry were obtained with fluorescence microscope. We performed this experiment with the antibody GFAP (gliocyte's marker) to label UC-MSCs-derived gliocyte. Images showed that the morphological changes of the transplanted UC-MSCs differentiated toward the glial cells (GFAP staining, Fig. 3).
FIGURE 3

Immunohistochemistry analysis of TBI rats what transplanted UC-MSCs or not. Transplanted UC-MSCs were stained with GFAP (red) and DAPI (blue) 4 weeks after transplantation. (A, B) Immunostaining of UC+TBI group rats after UC-MSCs transplantation. (C, D) Immunostaining of TBI group rats after PBS transplantation. TBI, traumatic brain injury; UC-MSCs, umbilical cord-derived mesenchymal stem cells.

Immunohistochemistry analysis of TBI rats what transplanted UC-MSCs or not. Transplanted UC-MSCs were stained with GFAP (red) and DAPI (blue) 4 weeks after transplantation. (A, B) Immunostaining of UC+TBI group rats after UC-MSCs transplantation. (C, D) Immunostaining of TBI group rats after PBS transplantation. TBI, traumatic brain injury; UC-MSCs, umbilical cord-derived mesenchymal stem cells.

The Secretion of the Neurotrophic Factors and Inflammatory Factors

To measure the role of the transplanted UC-MSCs in vivo, we used real-time quantitation PCR or enzyme linked immunosorbent assay (ELISA) to analyze the expression of neurotrophic factors, such as GDNF and BDGF from the tissue of damage or UC-MSCs transplantation. As the results described in Figure 4A and B, we found that the expression of GDNF and BDNF in TBI+UC-MSCs group was significantly higher than TBI group (P < 0.05).
FIGURE 4

The expression of the neurotrophic growth factors and the inflammatory factors. (A) The relative expression of GDNF in UC+TBI group and TBI group. (B) The relative expression of BDNF in TBI group and UC+TBI group. (C) The content of IL-1β in TBI group and UC+TBI group. (D) The content of TNF-αin TBI group and UC+TBI group.∗ P < 0.05, ∗∗∗P < 0.001; 2-tailed Student t test. TBI, traumatic brain injury; UC-MSCs, umbilical cord-derived mesenchymal stem cells; IL-1β, interleukin-lβ.

The expression of the neurotrophic growth factors and the inflammatory factors. (A) The relative expression of GDNF in UC+TBI group and TBI group. (B) The relative expression of BDNF in TBI group and UC+TBI group. (C) The content of IL-1β in TBI group and UC+TBI group. (D) The content of TNF-αin TBI group and UC+TBI group.∗ P < 0.05, ∗∗∗P < 0.001; 2-tailed Student t test. TBI, traumatic brain injury; UC-MSCs, umbilical cord-derived mesenchymal stem cells; IL-1β, interleukin-lβ. A lot of researches indicated that the survival of neuron after damage was closely connected with inflammatory factors in the surrounding microenvironment. So, we detected the content of inflammatory factors, such as interleukin-lβ (IL-1β) and tumor necrosis factor (TNF)-α by ELISA (Fig. 4C, D). Compared with TBI group, the content of inflammatory factors was lower in TBI+UC-MSCs group (P < 0.05).

DISCUSSION

Recent studies showed that the UC-MSCs could be induced into gliocyte-like cells, such as astrocytes and microglia cells which can secrete some neurotrophic factors to promote the survival of damaged neurons.[24,25] A large amount of cytokines were released in the damaged section, and played important roles in the cell death, recovery or survival, especially IL-1β and TNF-α, both are major inflammatory factors that can induce immune response. Meanwhile, GDNF and BDNF are neurotrophic factors which can promote nerve survival and recovery. Heo et al[11] reported that the transplanted stem cells can secrete some nerve growth factors, such as GDNF, BDNF, and NGF what could affect the survival of the ischemic nerve. The transplanted mesenchymal stem cell could mediate the immunomodulation by secreting the inflammatory factors.[26] Interleukin-lβ and TNF-α play an significant role in the immune response by recruiting macrophage and nature kill cells, increasing the cytotoxicity to damaged issue, and promoting cell apoptosis. But the roles of UC-MSCs have not been reported in TBI animal models. In our current study we investigated the roles of UC-MSCs after they were transplanted into TBI rats from the scores of NSS; the pathological changes between TBI group and UC+TBI group; the secretion of neurotrophic factors (GDNF and BDNF) and inflammatory factors (IL-1β and TNF-α). We isolated the UC-MSCs from umbilical cord of pregnant rats and cultured. To detect the characteristic of isolated UC-MSCs, we measured the biomarkers by flow cytometry. In our result, UC-MSCs were high expressed CD45 and CD29, which is consistent to the previous reports. Both behavior of TBI rats, and the morphology and density of neuron in damage area had a substantial improvement after UC-MSCs were transplanted, we detected the change of the behavior at 2 weeks after UC-MSCs were transplanted. We also detected the secretion of cytokines at the same time. The transplanted stem cells could secrete neurotrophic growth factors such as BDNF, GDNF to play the roles of therapy.[27,28] We found the expression of BDNF and GDNF were significantly increased. The expression level of the BDNF and GDNF in the UC-MSCs transplanted rat brains were observed by using ELISA kits from Promega Corporation, which demonstrated that the increase of neurotrophic factors in the area of transplanted UC-MSCs could improve the repair and regeneration of the neuron significantly.[29-31] The inflammation of damage area is a crucial factor in neuron regeneration. Interleukin-lβ is a member of the interleukin 1 family of inflammatory factors. Recent studies have implied that IL-1β could play a key role in mediating the inflammatory response after injury. Interleukin-lβ is also involved in many bioreactions in the central nervous system after damage; TNF-α is one of cytokines protein of signaling pathway involved in inflammation and apoptosis in damaged tissue. Both of them could recruit macrophage and nature killer cells and enhance the cytotoxicity to damaged issue and promote cell apoptosis, and they could be involved in cell proliferation, cell differentiation, and apoptosis.[32] To observe the importance of the inflammatory factors in TBI, we measured the content of IL-1β and TNF-α in the different groups by ELISA and immunohistochemistry. Both results showed that the level of the inflammatory factors in UC-MSCs TBI group was significantly lower than TBI group treated without UC-MSCs, which suggest that transplanted UC-MSCs can reduce the inflammatory response by downregulation of IL-1β and TNF-α expression. In conclusion, this study demonstrated that the transplanted UC-MSCs have a significant therapeutic effect in TBI models by upregulating the neurotrophic factors and downregulating the inflammatory factors. The increased neurotrophic factors might play an important role in the repair function by promoting the survival and cell proliferation in damaged area. Simultaneously, the decreased inflammatory factors could reduce immunoresponse and cell apoptosis. This study may provide a new therapeutic strategy in the nerve injury.
  31 in total

1.  Isolation, Culture, and Characterization of Human Umbilical Cord Blood-Derived Mesenchymal Stromal Cells.

Authors:  Karen Bieback; Philipp Netsch
Journal:  Methods Mol Biol       Date:  2016

2.  Determination of the therapeutic time window for human umbilical cord blood mononuclear cell transplantation following experimental stroke in rats.

Authors:  Johannes Boltze; Uwe R Schmidt; Doreen M Reich; Alexander Kranz; Klaus G Reymann; Maria Strassburger; Donald Lobsien; Daniel-Christoph Wagner; Annette Förschler; Wolf-Rüdiger Schäbitz
Journal:  Cell Transplant       Date:  2011-12-13       Impact factor: 4.064

3.  A new method for modulating traumatic brain injury with mechanical tissue resuscitation.

Authors:  Louis C Argenta; Zhenlin Zheng; Allyson Bryant; Stephen B Tatter; Michael J Morykwas
Journal:  Neurosurgery       Date:  2012-05       Impact factor: 4.654

4.  Correlation between chemokines released from umbilical cord blood-derived mesenchymal stem cells and engraftment of hematopoietic stem cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice.

Authors:  Yoo Hun Noh; Young Sook Yim; Dong Hyun Kim; Myoung Woo Lee; Dae Seong Kim; Hye Ryung Kim; Soo Hyun Lee; Hee Won Chueh; Soo Jin Choi; Won Il Oh; Yoon-Sun Yang; Hye Lim Jung; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo
Journal:  Pediatr Hematol Oncol       Date:  2011-11       Impact factor: 1.969

5.  Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice.

Authors:  Ning Wei; Shan Ping Yu; Xiaohuan Gu; Tammi M Taylor; Denise Song; Xin-Feng Liu; Ling Wei
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

6.  Neural transdifferentiation of human bone marrow mesenchymal stem cells on hydrophobic polymer-modified surface and therapeutic effects in an animal model of ischemic stroke.

Authors:  J S Heo; S-M Choi; H O Kim; E H Kim; J You; T Park; E Kim; H-S Kim
Journal:  Neuroscience       Date:  2013-02-20       Impact factor: 3.590

7.  [Immunomodulatory effect of UC-MSC on function of immunocytes of rats with collagen type II induced arthritis].

Authors:  Jian Gu; Chuan-Ming Lin; Wei Gu; Xin-Zhen Cai; Zou Li; Min-Min Ren; Xing Sun; Jun Ni; Lian-Jun Shen; Wei Wu; Bin He; Mei Sun; Yu Zhang
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2014-02

8.  Long-Term Survival Following Traumatic Brain Injury: A Population-Based Parametric Survival Analysis.

Authors:  Gordon W Fuller; Jeanine Ransom; Jay Mandrekar; Allen W Brown
Journal:  Neuroepidemiology       Date:  2016-05-11       Impact factor: 3.282

9.  Good manufacturing practice-compliant isolation and culture of human umbilical cord blood-derived mesenchymal stem cells.

Authors:  Phuc Van Pham; Ngoc Bich Vu; Vuong Minh Pham; Nhung Hai Truong; Truc Le-Buu Pham; Loan Thi-Tung Dang; Tam Thanh Nguyen; Anh Nguyen-Tu Bui; Ngoc Kim Phan
Journal:  J Transl Med       Date:  2014-02-24       Impact factor: 5.531

10.  Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity.

Authors:  Malte Krönig; Max Walter; Vanessa Drendel; Martin Werner; Cordula A Jilg; Andreas S Richter; Rolf Backofen; David McGarry; Marie Follo; Wolfgang Schultze-Seemann; Roland Schüle
Journal:  Oncotarget       Date:  2015-01-20
View more
  8 in total

1.  Human Umbilical Cord Mesenchymal Stem Cells for Severe Neurological Sequelae due to Anti-N-Methyl-d-Aspartate Receptor Encephalitis: First Case Report.

Authors:  Liem Nguyen Thanh; Van T Hoang; Huong Le Thu; Phuong Anh Thi Nguyen; Duc M Hoang; Doan Van Ngo; Hung Cao Vu; Van Nguyen Thi Bich; Michael Heke
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

Review 2.  Can Mesenchymal Stem Cells Act Multipotential in Traumatic Brain Injury?

Authors:  Fatemeh Dehghanian; Zahra Soltani; Mohammad Khaksari
Journal:  J Mol Neurosci       Date:  2020-01-02       Impact factor: 3.444

Review 3.  Neglected No More: Emerging Cellular Therapies in Traumatic Injury.

Authors:  Lacy E Lowry; Maryanne C Herzig; Barbara A Christy; Richard Schäfer; Shibani Pati; Andrew P Cap; James A Bynum
Journal:  Stem Cell Rev Rep       Date:  2021-01-08       Impact factor: 6.692

Review 4.  What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment?

Authors:  Qixin Xie; Rui Liu; Jia Jiang; Jing Peng; Chunyan Yang; Wen Zhang; Sheng Wang; Jing Song
Journal:  Stem Cell Res Ther       Date:  2020-12-01       Impact factor: 6.832

Review 5.  Mesenchymal Stem Cells for Neurological Disorders.

Authors:  Anna Andrzejewska; Sylwia Dabrowska; Barbara Lukomska; Miroslaw Janowski
Journal:  Adv Sci (Weinh)       Date:  2021-02-24       Impact factor: 16.806

Review 6.  Genetically Modified Mesenchymal Stem Cells: The Next Generation of Stem Cell-Based Therapy for TBI.

Authors:  Rami Ahmad Shahror; Chung-Che Wu; Yung-Hsiao Chiang; Kai-Yun Chen
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

Review 7.  The Role of BDNF in Experimental and Clinical Traumatic Brain Injury.

Authors:  David Gustafsson; Andrea Klang; Sebastian Thams; Elham Rostami
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

Review 8.  The Roles of Neurotrophins in Traumatic Brain Injury.

Authors:  Ping-Hung Lin; Lu-Ting Kuo; Hui-Tzung Luh
Journal:  Life (Basel)       Date:  2021-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.